b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31151809</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>22</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>22</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Print">1473-0502</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>58</Volume>\n                    <Issue>4</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Aug</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</Title>\n                <ISOAbbreviation>Transfus. Apher. Sci.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Management of acquired aplastic anemia in children : A single center experience.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>484-490</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S1473-0502(18)30373-2</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.transci.2019.05.004</ELocationID>\n            <Abstract>\n                <AbstractText>Acquired aplastic anemia (AAA) is a rare and potentially life threatening disorder. We retrospectively compared the outcomes of 29 children with AAA who received immunosuppressive therapy (IST) or underwent hematopoietic stem cell transplantation (HSCT). Median age at diagnosis was 9.0 years (range, 2-18 years) and median follow-up period was 36 months (range, 3-108 months). Viral infection associated/post hepatitis AAA was in 6 patients (20.6%). According to the initial laboratory findings, 8 patients were classified as very severe AA (vSAA), 8 as severe AA (SAA), and 13 patients as transfusion-dependent moderate AA (MAA). Out of 13, 5 transfusion-dependent MAA patients progressed SAA in median one month (range, 1-5 months), another 6 MAA patients developed remission or became transfusion free during follow-up. Eight patients underwent upfront matched family donor (MFD) HSCT at median 6 months (range, 1-9 months) and achieved complete response (100%). Fifteen cycles of IST were given to 10 (34%) patients lacking MFD at median 3 months (range, 2-6 months). Fifty percent of patients had complete/partial response after IST protocol. Three patients who were unresponsive to IST, proceeded to alternative donor HSCT, in 2nd or 3rd year after the diagnosis and only 1 patient was sustained remission. Several drugs such as mycophenolatemofetil, high-dose cyclophosphamide, levamisole and eltrombopag have been investigated in order to improve the outcome of patients with AAA. Early intervention in AAA patients results in significantly better outcomes.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Yazal Erdem</LastName>\n                    <ForeName>Arzu</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Department of Pediatric Hematology and Oncology, Turkey. Electronic address: arzu.erdem@gmail.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Arman Bilir</LastName>\n                    <ForeName>\xc3\x96zlem</ForeName>\n                    <Initials>\xc3\x96</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Department of Pediatric Hematology and Oncology, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>I\xc5\x9f\xc4\xb1k</LastName>\n                    <ForeName>Melek</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Department of Pediatric Hematology and Oncology, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ka\xc3\xa7ar</LastName>\n                    <ForeName>Dilek</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Department of Pediatric Hematology and Oncology, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>\xc3\x96zbek</LastName>\n                    <ForeName>Nam\xc4\xb1k Ya\xc5\x9far</ForeName>\n                    <Initials>NY</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Department of Pediatric Hematology and Oncology, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yaral\xc4\xb1</LastName>\n                    <ForeName>H\xc3\xbcsniye Ne\xc5\x9fe</ForeName>\n                    <Initials>HN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Department of Pediatric Hematology and Oncology, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D003160">Comparative Study</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>05</Month>\n                <Day>10</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Transfus Apher Sci</MedlineTA>\n            <NlmUniqueID>101095653</NlmUniqueID>\n            <ISSNLinking>1473-0502</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D001565">Benzoates</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D006834">Hydrazines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>2880D3468G</RegistryNumber>\n                <NameOfSubstance UI="D007978">Levamisole</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>8N3DW7272P</RegistryNumber>\n                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>S56D65XJ9G</RegistryNumber>\n                <NameOfSubstance UI="C520809">eltrombopag</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <SupplMeshList>\n            <SupplMeshName Type="Disease" UI="C538494">Aplastic anemia, idiopathic</SupplMeshName>\n        </SupplMeshList>\n        <CitationSubset>T</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D064591" MajorTopicYN="N">Allografts</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000741" MajorTopicYN="N">Anemia, Aplastic</DescriptorName>\n                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001565" MajorTopicYN="N">Benzoates</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006834" MajorTopicYN="N">Hydrazines</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007165" MajorTopicYN="Y">Immunosuppression</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007978" MajorTopicYN="N">Levamisole</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Acquired aplastic anemia</Keyword>\n            <Keyword MajorTopicYN="N">Child</Keyword>\n            <Keyword MajorTopicYN="N">Levamisole</Keyword>\n            <Keyword MajorTopicYN="N">Treatment</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>09</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>25</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>05</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>4</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>2</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31151809</ArticleId>\n            <ArticleId IdType="pii">S1473-0502(18)30373-2</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.transci.2019.05.004</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'